Providing Predictive and Prognostic Biomarkers for Breast Cancer From the TAILORx Trial
September 6th 2019Jesus Anampa, MD, MS, assistant professor, Department of Medicine, Albert Einstein School of Medicine, says in the past, most patients with breast cancer were treated with chemotherapy. In some cases, these patients were being over-treated. To limit the use of chemotherapy in patients who don’t need it, a group of researchers conducted the TAILORx trial.
Watch
Combination Regimen Options Under Investigation in Melanoma
September 5th 2019Keith T. Flaherty, MD, discusses the combination regimens and the potential role for a 3-drug regimen as treatment for patients with melanoma. He says investigators have been searching for new combination strategies beyond the combination of BRAF and MEK inhibitors.
Watch
Analyzing Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer
September 4th 2019Angela DeMichele, MD, MSCE, discusses predictors of response to neoadjuvant chemotherapy in various subgroups of patients with breast cancer. Selecting characteristics of patients who will most likely benefit from this therapy is not an exact science, she adds.
Watch
Considering the Role of Clinical Trials for Patients With Molecularly Altered Lung Cancers
September 3rd 2019Sarah B. Goldberg, MD, MPH, discusses the role of clinical trials in patients with lung cancer who have molecularly altered tumors, such as <em>EGFR</em>, <em>ALK</em>, <em>BRAF</em>,<em>ROS1, </em>or other alterations. These patients typically consider either targeted therapy or immunotherapy treatment options.
Watch
Targeted Agents Evolve in Anaplastic, Medullary Thyroid Cancer Treatment Paradigms
August 28th 2019Andrew Turk, MD, discusses targeted agents that are making a splash in the treatment landscape of thyroid cancers, including the most aggressive form of the disease, anaplastic thyroid carcinoma. He says targeted agents have already become well established in the space of thyroid cancers, but these agents continue to evolve.
Watch
Discussing the Benefits of Trilaciclib Plus Topotecan for Treatment of Extensive-stage SCLC
August 27th 2019Lowell L. Hart, MD, FACP, scientific director of clinical research, Florida Cancer Specialists & Research Institute, and associate professor of medicine, Wake Forest University School of Medicine, discusses the effect of CDK4/6 inhibitor, trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. Hart presented the phase II results from the blinded, multicenter study during the 2019 ASCO Annual Meeting.
Watch
Nivolumab/Ipilimumab Combination Data Promising in MSI-H/dMMR mCRC
August 27th 2019Heinz-Josef Lenz, MD, discusses the significance of the latest updates in the CheckMate 142 trial exploring an immunotherapy treatment combination in patients with metastatic colorectal cancer whose tumors are microsatellite instability–high or mismatch repair deficient.
Watch
Exploring Approaches to Treating Different Subgroups of Mantle Cell Lymphoma
August 26th 2019Peter Martin, MD, discusses the differences between subgroups of mantle cell lymphoma. MCL is a heterogenous disease, and in the World Health Organization classification of lymphoid neoplasms, MCL has a leukemia non-nodal presentation, says Martin.
Watch